Basel, Switzerland: MDPI: 185
BPC-157 has shown promising results in preclinical research for treating various conditions, including muscle and tendon injuries, gastrointestinal disorders, and inflammation
In the event of supply shortages, other FDA-approved products may be available
Schedule a consultation to learn how our peptide therapies can benefit you
showed the relationships between eNAP-2 and several four-disulfide core antiproteases and also the relationships between eNAP-2 and equine cationic peptides exhibiting selective inhibitory activity against subtilisin and proteinase K (later denoted equinins), reported by Pellegrini et al
Early studies show promising healing and recovery benefits, especially in tissue repair